Abstract
Children and adults with congenital heart disease (CHD) can require interventions that result in immunologic alterations that are different than those seen in patients with cardiomyopathies. Patients with CHD can be exposed to heart surgeries, blood products, valved and non-valved allograft tissue, and mechanical circulatory support, all of which can alter the immunologic status of these patients. This change in immunologic status is most commonly manifested as the development of anti-human leukocyte antigen (HLA) antibodies. This review will delineate a) the causes of anti-HLA antibody production (often referred to as allosensitization); b) preventive strategies for anti-HLA antibody production before transplantation; c) treatment strategies for those patients who develop anti-HLA antibodies before transplantation; d) consequences of HLA allosensitization after transplantation; and e) treatment of HLA allosensitization and antibody-mediated rejection after transplantation.
Keywords: Heart transplantation, allosensitization, rejection, pediatric, therapy, management, ANTI-HLA ANTIBODY, PREVENTIVE STRATEGIES, anti-HLA, irradiation, cardiopulmonary bypass, immune response
Current Cardiology Reviews
Title: Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Volume: 7 Issue: 2
Author(s): Beth D. Kaufman and Robert E. Shaddy
Affiliation:
Keywords: Heart transplantation, allosensitization, rejection, pediatric, therapy, management, ANTI-HLA ANTIBODY, PREVENTIVE STRATEGIES, anti-HLA, irradiation, cardiopulmonary bypass, immune response
Abstract: Children and adults with congenital heart disease (CHD) can require interventions that result in immunologic alterations that are different than those seen in patients with cardiomyopathies. Patients with CHD can be exposed to heart surgeries, blood products, valved and non-valved allograft tissue, and mechanical circulatory support, all of which can alter the immunologic status of these patients. This change in immunologic status is most commonly manifested as the development of anti-human leukocyte antigen (HLA) antibodies. This review will delineate a) the causes of anti-HLA antibody production (often referred to as allosensitization); b) preventive strategies for anti-HLA antibody production before transplantation; c) treatment strategies for those patients who develop anti-HLA antibodies before transplantation; d) consequences of HLA allosensitization after transplantation; and e) treatment of HLA allosensitization and antibody-mediated rejection after transplantation.
Export Options
About this article
Cite this article as:
D. Kaufman Beth and E. Shaddy Robert, Immunologic Considerations in Heart Transplantation for Congenital Heart Disease, Current Cardiology Reviews 2011; 7 (2) . https://dx.doi.org/10.2174/157340311797484204
DOI https://dx.doi.org/10.2174/157340311797484204 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |
Call for Papers in Thematic Issues
Advances in Managing Cardiogenic Shock and the Value of Percutaneous Mechanical Circulatory Support.
Despite the advances in cardiology, the outcomes of patients with cardiogenic shock remain poor. There is an increasing interest and use of mechanical circulatory support for patients with cardiogenic shock. Additionally, the complexity of coronary interventions has increased during the last decade with the potential of treating more high-risk patients ...read more
Artificial Intelligence (AI) in cardiovascular disease
Artificial Intelligence (AI) in cardiovascular disease is an emerging interdisciplinary field that integrates advanced technologies to improve patient care. The current AI landscape faces significant challenges, including the complexity of diagnosing and treating these conditions. Recent studies have shown promising results in the use of AI for early detection, diagnosis, ...read more
Chronic Disease Self-Management for Heart Failure – A Mini Review into Performance Gaps
Chronic disease self-management (CDSM)is a vital component of chronic disease management. There remain several important deficits in this concept. Its benefit are clear, many chronic diseases such as hypertension, diabetes, asthma, rheumatology syndromes have shown benefit in quality of life and quantitative measures of outcomes. Yet, in congestive heart failure ...read more
The era of cardiac medication and implantable devices therapy in heart failure treatment continues
The heart failure (HF) remains a serious public health problem and affects 64 million people worldwide. Although advances in medical therapy and device assistance have significantly improved HF outcomes, the implications of HF are still dramatic. In recent years, innovative developments have been made in HF treatment management, based on ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders
Current Gene Therapy Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Fetal Cardiac Cellular Damage Caused by Anemia in Utero in Hb Bart’s Disease
Current Molecular Medicine The Potential of Melatonin to Treat Atherosclerosis by Targeting Mitochondria
Current Topics in Medicinal Chemistry Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis
Current Medicinal Chemistry CD36 and Intestinal Fatty Acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Editorial [Hot topic: Innate Immunity Molecules S100A8/A9 Involved in Stress Response and Cancer Biology (Guest Editors: Claus Kerkhoff and Saeid Ghavami)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry Anti Diabetic Evaluation of Methanolic Extract of <i>Psoralea corylifolia</i> L. & <i>Psoralea esculenta</i> L. Seeds in Streptozotocin Induced Diabetic Rats and Histopathological Changes in Diabetic Rats Pancreas: A Comparative Study
The Natural Products Journal A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Protein Misfolding Diseases and Therapeutic Approaches
Current Protein & Peptide Science The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology